Suboxone (buprenorphine and naloxone) was approved by the FDA in 2002 for the treatment of opioid addiction. It was the first medication approved to treat opioid dependence that could be prescribed or dispensed in doctor's offices instead of requiring patients to receive treatment in specialist facilities or hospitals. This regulatory approval helped address a shortage of treatment options and made medication-assisted treatment more accessible across the country.
Within a few years of approval, Suboxone prescriptions grew exponentially as more doctors were allowed to prescribe the medication after completing training. The convenience of office-based treatment combined with Suboxone's effectiveness quickly made it one of the most commonly used treatments for opioid use disorder (OUD) in the United States.
Increasing Rates Of Opioid Addiction Drive United States Of America Suboxone
As the opioid crisis intensified across the U.S. in the late 2000s and early 2010s, rates of opioid abuse and overdose deaths skyrocketed. This created an enormous rise in demand for medication-assisted treatment with buprenorphine-containing products like Suboxone. Multiple interventions were introduced at both federal and state levels to expand access to these life-saving medications during this time. The Affordable Care Act required most commercial insurance plans to cover substance abuse and mental health treatment, making medication-assisted treatment more affordable. State Medicaid programs also expanded coverage of buprenorphine treatment. These changes helped eliminate many financial barriers for people seeking addiction treatment. With increasing availability and affordability of Suboxone, its use continued growing rapidly throughout the 2010s as physicians and patients embraced it as a frontline intervention for the opioid crisis.
Suboxone Manufacturers Expand Production Capacity
As total prescriptions for Suboxone soared during the late 2000s, meeting the growing demand posed a major challenge for its manufacturers - Indivior and Dr. Reddy's Laboratories. Both companies had to rapidly scale up production capacity at their manufacturing plants. They invested heavily in expanding production lines, hiring and training more employees, and acquiring raw material suppliers to keep up with the surge in orders from pharmacies and distributors across the nation. However, it still took time for manufacturing output to catch up to prescription volume increases. This led to intermittent supply shortages of Suboxone film and tablets during 2008-2012 in certain regions of the US. The manufacturers were able to resolve these issues by 2012 as their expanded facilities came online. Now, with stable and sufficient domestic production, US orders for Suboxone can be fulfilled without any disruption in supply.
Physician Waivers And Improvement In Access
An important regulatory change that helped address treatment capacity issues was relaxing restrictions on buprenorphine prescribing through the Drug Addiction Treatment Act of 2000 (DATA 2000). Previously, only physicians with addiction specialists training could prescribe buprenorphine products like Suboxone through a process requiring a waiver from SAMHSA. In 2007 and 2016, policies were amended to allow more general practitioners to gain waivers after completing training programs. This vastly increased the number of clinicians eligible to treat OUD using buprenorphine. By 2018, over 74,000 waivered practitioners were providing treatment across rural and urban areas compared to only around 2,500 in 2002. Improved prescriber availability combined with insurance coverage expansion ensured medication-assisted therapy reached many more communities suffering from the opioid crisis. More OUD patients were able to access Suboxone treatment closer to home without long wait times.
Burgeoning Suboxone Generating Billions
Due to rising addiction rates and barriers to treatment falling nationwide, the total commercial value of the buprenorphine has ballooned over the past 15 years. In 2021, total US retail sales revenue for buprenorphine products including Suboxone film, tablets and generics surpassed $3.2 billion according to prescription data firms. This represents exponential growth from just $300 million in 2006 prior to the height of the opioid epidemic. Currently, Suboxone holds around 70% share of the buprenorphine with its exclusive film formulation controlling over half of revenue. Indivior had dominated global sales as the original manufacturer but now faces rising competition from generics as patents expire. Despite price declines, overall US size continues rising as treatment rates rise proportionately with worsening addiction statistics. Analysts project the buprenorphine could reach $4-5 billion levels in the next few years driven by ongoing expansion of access and need across American communities.
Role Of Telehealth In Ensuring Continuity Of Care
When the COVID-19 pandemic struck in early 2020, many OUD treatment centers had to temporarily shut down to comply with lockdown restrictions. This posed risks of disrupting life-saving medication-assisted therapy for hundreds of thousands dependent on buprenorphine treatment nationwide. However, SAMHSA and DEA quickly issued guidance allowing clinicians to conduct buprenorphine inductions and provide refill prescriptions through telehealth technology during public health emergencies. This enabled Suboxone prescribers to transition many stable patients onto virtual care and mail-order pharmacy services overnight. Telehealth enabled continuity of care without unnecessary interruptions to MAT access during a time sensitive period for addiction treatment. Despite initial difficulties, all stakeholders worked collaboratively to leverage technology and minimize public health impacts on those undergoing treatment. As a result of pandemic response success, permanent expansion of telehealth for MAT is under active consideration to boost access across rural areas.
In Suboxone has emerged as a critical frontline intervention in combating the devastating opioid crisis impacting American communities. Changes from regulatory approvals to healthcare policies have helped address barriers and scale up treatment infrastructure. Increased medication access through expanding provider networks and telehealth has saved many lives dependent on buprenorph.
Get more insights on this topic: https://www.trendingwebwire.com/united-states-of-america-suboxone-understanding-suboxone-treatment-in-the-united-states/
Author Bio
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups. (LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
Comments
0 comment